In a letter sent today to the drug maker, the committee maintained Valeant has repeatedly declined to provide a list of documents requested two months ago as part of its investigation into Valeant pricing. The committee wants to know more about the rights to a pair of life-saving heart drugs — Nitropress and Isuprel — that Valeant purchased and, on the same day, raised list prices by 525 percent and 212 percent, respectively.
Read Full Article »
